Novo Nordisk now sells semaglutide for weight management in two forms: the original weekly injection and Wegovy Tablets, an oral version you take each morning at home. On Wegovy tablets vs Wegovy injection, the short answer is that both carry the same active molecule and neither is universally better. The differences that matter are practical, financial and specific to how your body handles an oral GLP-1. We prescribe both and bill them at pharmacy cost with zero markup. This is the comparison we give patients when they ask.
An oral GLP-1 is not a small thing. For the roughly half of patients who hesitate at needles or the many who travel constantly, the pill removes the logistical friction that quietly ends treatment. But oral semaglutide demands something the injection does not: a fasting stomach and a patient who follows the morning ritual precisely, every day, because absorption depends on it.
- Wegovy injection and Wegovy Tablets both use semaglutide, the active molecule is identical.
- STEP-1: the injection averaged 14.9% weight loss at 68 weeks. OASIS 4: the tablet averaged 13.6% weight loss at 64 weeks.
- The tablet must be taken fasting each morning, with about a 30-minute wait before food, drink or other medication.
- Self-pay pricing runs roughly $499 to $650 per month for the injection versus around $149 per month for the tablet at the lowest dose.
- GoodLife Health's $299 per month membership covers the doctor and the quarterly Biomarker Audit. The medicine is a separate charge at exactly pharmacy cost.
- Foundayo (orforglipron), approved April 1, 2026, has no fasting requirement and showed average 12.4% weight loss among completers in ATTAIN-1.
The two forms side by side
The two forms side by side
Semaglutide is the shared active molecule in both formulations
| Dimension | Wegovy injection | Wegovy Tablets |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide |
| Administration | Subcutaneous injection once weekly | Oral tablet daily, taken fasting in the morning |
| How to take it | Inject any time on your chosen day | Empty stomach with a small amount of water, wait about 30 minutes before food, drink or other medication |
| Titration | Dose steps over months under physician guidance | Dose steps over months, with an absorption ceiling at higher doses |
| Effect size | STEP-1: average 14.9% weight loss at 68 weeks | OASIS 4: average 13.6% weight loss at 64 weeks |
| Common side effects | Nausea, diarrhea, constipation, fatigue | Same GLP-1 class effects, sometimes more gastrointestinal at dose steps |
| Best for | Patients who want maximum absorption and a weekly routine | Patients avoiding needles, frequent travelers, those on predictable morning schedules |
The effect-size figures come from the respective registrational trials, STEP-1 for the injection and OASIS 4 for the oral formulation and they were measured in different populations under different protocols, so the percentages are directional rather than head-to-head. Both formulations produce clinically meaningful weight loss, individual results vary and either one administered without the lifestyle structure and monitoring around it underperforms what the trials show.
What the trials actually showed
The injection's evidence is the deepest in the class. STEP-1 randomized adults with obesity or overweight with comorbidity to semaglutide 2.4 mg weekly or placebo with lifestyle counseling and the treated group lost an average of 14.9% of body weight over 68 weeks, with cardiovascular benefit data following in SELECT [1].
The oral story is newer. Wegovy Tablets was approved in the United States in January 2026 based on the OASIS 4 program, in which adults taking oral semaglutide 25 mg daily lost an average of 13.6% of body weight over 64 weeks, compared with 0.8% on placebo [2]. The FDA approval made it the first oral GLP-1 for chronic weight management, distinct from Rybelsus, the earlier oral semaglutide product approved for type 2 diabetes.
Those trial numbers were produced with structured lifestyle support and scheduled monitoring. That context matters, because the most common failure mode we see in real-world GLP-1 care is not the wrong drug. It is the right drug administered by nobody, with no titration plan, no side-effect management and no one watching the lean mass, the thyroid panel and the lipids while the scale moves.
The most common failure mode we see in real-world GLP-1 care is not the wrong drug. It is the right drug administered by nobody, with no titration plan, no side-effect management and no one watching the lean mass, the thyroid panel and the lipids while the scale moves.
The absorption rules that decide whether the pill works
Oral semaglutide has an absorption profile unlike almost any other prescription you will take. It is absorbed through the stomach lining and requires the stomach to be empty:
- Take it first thing in the morning, on waking, with no more than a small sip of water.
- Wait at least 30 minutes before eating, drinking anything besides water or taking other medications.
- Do not skip the ritual. Food in the stomach cuts absorption substantially and the trial results assume the regimen as studied.
- Coordinate your morning medications. Levothyroxine and several other drugs need spacing. Your physician and pharmacist should map the morning schedule with you.
A patient who cannot protect that thirty-minute window reliably will get inferior results from the tablet and should probably use the injection. A patient with a stable morning routine or one whose biggest obstacle was the needle, may find the tablet transforms adherence. This is a conversation about your actual life, which is why it happens with a physician rather than at checkout on an app.
A patient who cannot protect that thirty-minute window reliably will get inferior results from the tablet and should probably use the injection. A patient with a stable morning routine or one whose biggest obstacle was the needle, may find the tablet transforms adherence.


How each is priced and how we handle the money
Both are self-pay-friendly now. The injection remains available through NovoCare Pharmacy at commonly reported self-pay pricing of roughly $499 to $650 per month depending on pathway. Wegovy Tablets launched with a self-pay pathway commonly reported around $149 per month at the lowest dose, which undercuts nearly everything else in the branded class [2]. Prices shift and promotions change, so treat these as hedges rather than guarantees and verify current terms when you decide.
In our model, whichever form your physician prescribes, the pharmacy bills you directly at pharmacy cost with zero markup from us. The $299 per month membership covers the doctor and the quarterly Biomarker Audit. The medicine is a separate charge, at exactly what it costs. No molecule upcharge, no dose-escalation fee. If your care eventually titrates to a higher dose, our fee does not move and the pharmacy's price is the pharmacy's price.
That structure matters more than it looks. Platforms that sell GLP-1s with the fee bundled into the medicine have a structural incentive to keep the prescription growing. We do not, because the doctor's fee is flat and the medicine is pass-through. Our clinical guidance has no profit motive in your dose, in either direction.
How we decide which form fits you
The decision is clinical and it weighs:
- Gastrointestinal history. Oral dosing sometimes produces more pronounced nausea at dose steps. Patients with sensitive systems may tolerate the gradual injection titration better.
- Your mornings. Shift work, early flights, unpredictable schedules and coffee habits all argue for the injection.
- Needle aversion. Real and common. If the needle was going to end your treatment in week three, the tablet is the right call.
- Current medications. Morning medication schedules, especially thyroid replacement, need mapping before the tablet is chosen.
- Metabolic context. Your Biomarker Audit informs the entire GLP-1 decision, starting with whether one is appropriate at all and the choice between formulations is made against that same picture.
Either choice is monitored through the same quarterly Audits: weight and body composition trajectory, HbA1c, lipids, ApoB, hs-CRP, thyroid and hormone panels. Medication decisions are revisited against those results and de-escalation is on the table whenever the data supports it, because our fee has no stake in your dose.
The objection we hear most: is the pill a weaker version
Some patients assume oral means diluted. The honest answer is that the tablet delivers a somewhat lower average effect in its trial than the injection delivered in its trial, with the caveat that cross-trial comparisons are imperfect and that for many patients the difference is smaller than the adherence difference. The most effective formulation is the one you will actually take correctly for years and that calculus favors the pill for a substantial group of patients. If maximal pharmacologic effect is the priority and your mornings are chaotic, the injection likely wins. If adherence was the risk, the tablet likely does.
The most effective formulation is the one you will actually take correctly for years.
On choosing between Wegovy injection and Wegovy Tablets
There is also Foundayo (orforglipron), the oral GLP-1 approved April 1, 2026, which takes without fasting requirements and showed an average 12.4% weight loss among completers at the highest dose in ATTAIN-1 [3]. It is a legitimate branded alternative in the same conversation and your physician can compare all three against your labs and your schedule.
FAQ
Are Wegovy Tablets the same drug as Wegovy injection?
Yes. Both contain semaglutide. The tablet is a daily oral formulation taken fasting, while the injection is a weekly subcutaneous dose.
How much weight do people lose on Wegovy Tablets?
In the OASIS 4 trial, participants lost an average of 13.6% of body weight over 64 weeks versus 0.8% on placebo. Individual results vary and the regimen requires the fasting morning routine as studied.
Do I have to fast before taking Wegovy Tablets?
Yes. Take it on waking with a small amount of water and wait about 30 minutes before food, other beverages or medications. Food in the stomach significantly reduces absorption.
Which is cheaper, the tablet or the injection?
The tablet's self-pay pathway has been commonly reported around $149 per month at the lowest dose, versus roughly $499 to $650 per month for the injection through self-pay channels. Verify current pricing when you decide.
Can I switch between the tablet and the injection?
Yes, under physician guidance, with appropriate dose conversion and monitoring. The transition is straightforward and is a normal part of ongoing care.
Is Wegovy Tablets approved for weight loss?
Yes. The FDA approved it in January 2026 as the first oral GLP-1 for chronic weight management, distinct from Rybelsus, which is approved for type 2 diabetes.
Does GoodLife Health prescribe both forms?
Yes, when clinically appropriate, alongside the full branded GLP-1 menu including Zepbound, Mounjaro, Ozempic and Foundayo. Medication is billed separately by the pharmacy at pharmacy cost with zero markup.
What does the membership cost?
One flat $299 per month, no tiers, beginning with a $598 first charge for the initial two-month commitment. The comprehensive Biomarker Audit every 90 days is included.
One last thing
The best formulation question is really an adherence question and adherence is a design problem, not a character test. Choose the form that fits the life you actually live, have a physician monitor what it does to your entire metabolic system and let the quarterly data decide whether the plan continues, adjusts or simplifies. That is how this medication is supposed to be used, in either form.
Related guides
- Medical weight loss at GoodLife Health
- Zepbound cash-pay pricing: the real math
- Compounded GLP-1 vs brand name: what patients need to know
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/